Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 5/20 | 0.53 |
| ▸ | MMP1 | P03956 | 4/20 | 0.53 |
| ▸ | MMP2 | P08253 | 4/20 | 0.53 |
| ▸ | MMP8 | P22894 | 4/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8838880 | 1.00 | MEN1 (0.54) | MEN1ALDH1A1KMT2AP2RX7MMP9 | |
| SCHEMBL29676862 | 1.00 | MEN1 (0.54) | MEN1ALDH1A1KMT2AP2RX7MMP9 | |
| SCHEMBL2442157 | 1.00 | MEN1 (0.54) | MEN1ALDH1A1KMT2AP2RX7MMP9 | |
| SCHEMBL8017602 | 1.00 | MEN1 (0.54) | MEN1ALDH1A1KMT2AP2RX7MMP9 | |
| SCHEMBL7740807 | 1.00 | MEN1 (0.54) | MEN1ALDH1A1KMT2AP2RX7MMP9 | |
| SCHEMBL3328510 | 0.85 | NAMPT (0.52) | MEN1ALDH1A1KMT2AP2RX7MMP9 | |
| SCHEMBL5802535 | 0.85 | NAMPT (0.52) | MEN1ALDH1A1KMT2AP2RX7MMP9 | |
| SCHEMBL18141994 | 0.85 | NAMPT (0.52) | MEN1ALDH1A1KMT2AP2RX7MMP9 | |
| SCHEMBL1665424 | 0.85 | NAMPT (0.52) | MEN1ALDH1A1KMT2AP2RX7MMP9 | |
| SCHEMBL17923298 | 0.85 | NAMPT (0.52) | MEN1ALDH1A1KMT2AP2RX7MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148537-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-04-03 | — | — | US | claimed |
| EP-2125736-B1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA AS (DK) | 2011-03-30 | — | — | EP | claimed |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA (DK) | 2010-02-11 | — | — | US | claimed |
| CN-101611005-A | Be used as the acetophenones of the replacement of PDE4 inhibitor | LEO PHARMA AS (DK) | 2009-12-23 | — | — | CN | claimed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | claimed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | claimed |
| US-5516943-A | Process for preparing cyclic CIS-1-amino-2-alkanols | SEPRACOR, INC. (US) | 1996-05-14 | — | — | US | claimed |
| EP-2931724-B1 | PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS | PURDUE PHARMA LP (US) | 2017-01-25 | — | — | EP | disclosed |
| US-9403824-B2 | Pyridonemorphinan analogs and biological activity on opioid receptors | PURDUE PHARMA L.P. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9340542-B2 | Propellane-based compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150203494-A1 | PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS | PURDUE PHARMA L.P. | 2015-07-23 | — | — | US | disclosed |
| WO-2015097546-A1 | PROPELLANE-BASED COMPOUNDS AND THEIR USE AS OPIOID RECEPTOR MODULATORS | PURDUE PHARMA L.P. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-20150183787-A1 | PROPELLANE-BASED COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2015-07-02 | — | — | US | disclosed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | disclosed |
| US-5760242-A | Method of producing a cis-oxazoline | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1998-06-02 | — | — | US | disclosed |
| US-5648534-A | Method of producing cis-1-aminoindan-2-ol | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1997-07-15 | — | — | US | disclosed |
| US-5616808-A | Optically pure 1-amino-2-indanols | SEPRACOR, INC. (US) | 1997-04-01 | — | — | US | disclosed |
| US-5599985-A | Optically pure 1-amido-2-indanols | SEPRACOR, INC. (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0658537-A1 | Method of producing cis-1-aminoindan-2-ol | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1995-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183787-A1 | PROPELLANE-BASED COMPOUNDS AND THE USE THEREOF | OPRL1, OPRK1, OPRD1 | MEN1 3121/4885ALDH1A1 214/4885KMT2A 4550/4885 |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3B | MEN1 4170/4885ALDH1A1 457/4885KMT2A 3607/4885 |
| US-20150203494-A1 | PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS | OPRM1, OPRK1, OPRL1 | MEN1 4434/4885ALDH1A1 704/4885KMT2A 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.